Comment on

• Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

  Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Dahlöf B, et al. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. Lancet. 2002. PMID: 11937178 Clinical Trial.
• Was the LIFE trial independent?

  Van Brabandt H. Van Brabandt H. Lancet. 2002 Oct 12;360(9340):1171; author reply 1171. doi: 10.1016/S0140-6736(02)11212-8. Lancet. 2002. PMID: 12387973 No abstract available.
• Was the LIFE trial independent?

  Vandenbroucke JP. Vandenbroucke JP. Lancet. 2002 Oct 12;360(9340):1171; author reply 1171. doi: 10.1016/S0140-6736(02)11211-6. Lancet. 2002. PMID: 12387974 No abstract available.